Welcome to CDC stacks | Antiviral agents for the treatment and chemoprophylaxis of influenza; recommendations of the Advisory Committee on Immunization Practices (ACIP) - 5855 | Stephen B. Thacker CDC Library collection | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Antiviral agents for the treatment and chemoprophylaxis of influenza; recommendations of the Advisory Committee on Immunization Practices (ACIP)
  • Published Date:
    January 21, 2011
  • Status:
    current
Filetype[PDF-24.76 MB]


This document cannot be previewed automatically as it exceeds 5 MB
Please click the thumbnail image to view the document.
Antiviral agents for the treatment and chemoprophylaxis of influenza; recommendations of the Advisory Committee on Immunization Practices (ACIP)
Details:
  • Corporate Authors:
    United States. Advisory Committee on Immunization Practices. ; National Center for Immunization and Respiratory Diseases (U.S.) ; National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. ; ... More ▼
  • Description:
    Introduction -- Methods -- Primary changes and updates in the recommendations -- Influenza virus transmission -- Clinical signs and symptoms of influenza -- Role of laboratory diagnosis -- Antiviral agents for influenza. Antiviral drug resistance among influenza viruses ; Use of antivirals ; Dosage ; Adverse events ; Drug interactions ; Emergency use authorization -- Additional information.

    "This report updates previous recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of antiviral agents for the prevention and treatment of influenza (CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2008;57[No. RR-7]).This report contains information on treatment and chemoprophylaxis of influenza virus infection and provides a summary of the effectiveness and safety of antiviral treatment medications. Highlights include recommendations for use of 1) early antiviral treatment of suspected or confirmed influenza among persons with severe influenza (e.g., those who have severe, complicated, or progressive illness or who require hospitalization); 2) early antiviral treatment of suspected or confirmed influenza among persons at higher risk for influenza complications; and 3) either oseltamivir or zanamivir for persons with influenza caused by 2009 H1N1 virus, influenza A (H3N2) virus, or influenza B virus or when the influenza virus type or influenza A virus subtype is unknown; 4) antiviral medications among children aged <1 year; 5) local influenza testing and influenza surveillance data, when available, to help guide treatment decisions; and 6) consideration of antiviral treatment for outpatients with confirmed or suspected influenza who do not have known risk factors for severe illness, if treatment can be initiated within 48 hours of illness onset. Additional information is available from CDC's influenza website at http://www.cdc.gov/flu, including any updates or supplements to these recommendations that might be required during the 2010--11 influenza season. Health-care providers should be alert to announcements of recommendation updates and should check the CDC influenza website periodically for additional information. Recommendations related to the use of vaccines for the prevention of influenza during the 2010--11 influenza season have been published previously (CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices [ACIP], 2010. MMWR 2010;59[No. RR-8])." - p. 1

  • Document Type:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: